ASX: RCE

$0.0

ASX: RCE

$0.0

ASX: RCE

$0.0

Events and Presentations

  • Home
  • Right Arrow-svg Investor & Media
  • Right Arrow-svg Events and Presentations

Resources

Fact Sheets & Posters

2024 Edison Group - Research Report

View

Eye Icon-svg

PDF

2023 MST Access - Update Report

View

Eye Icon-svg

PDF

2024 Fact Sheet

View

Eye Icon-svg

PDF

2023 Recce Scientific Poster

View

Eye Icon-svg

PDF

Presentations

2024 Corporate Presentation - April 2024

View

Eye Icon-svg

PDF

2023 World AMR Congress 2023 - Presentation

View

Eye Icon-svg

PDF

Whitepapers & Abstracts

2023 ESKAPE overview

View

Eye Icon-svg

PDF

2023 ESCMID/ASM - Abstract

View

Eye Icon-svg

PDF

2021 Mechanism of Action - Abstract

View

Eye Icon-svg

PDF

2023 Whitepaper

View

Eye Icon-svg

PDF

Annual Reports

2023 Annual Report 2023

View

Eye Icon-svg

PDF

2022 Annual Report 2022

View

Eye Icon-svg

PDF

2021 Annual Report 2021

View

Eye Icon-svg

PDF

2020 Annual Report 2020

View

Eye Icon-svg

PDF

Quick Links

About Us

Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.

Stay up to date

Receive news and information direct to your inbox.
Twitter Linkedin-in Youtube

© 2024 Recce Pharmaceuticals